ICYMI: Increased SLE Flares with HCQ Reduction Concerns about the long-term safety of HCQ often results in dose reduction or drug discontinuation; study shows that, for those in remission, HCQ taper/discontinuation resulted in a higher rate of SLE flares. https://t.co/l0Xh1oQzQA https://t.co/HyDbqKrEFp